GLP-1 use linked to lower breast cancer incidence in large cohort study

medicalxpress - A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presente…

AI Summary: A large observational cohort study reported an association between GLP‑1 agonist use and a lower incidence of breast cancer. The result is intriguing and may spur biological investigation, but researchers caution against causal claims—confounding and indication bias mean randomized trials would be required to confirm any protective effect.

#obesity #pharmaceuticals #weightloss #drugdevelopment #oncology #cancerresearch #clinicaltrials #diabetes

2 months / bbc

2 months / sciencedaily

2 months / medicalxpress

2 months / medicalxpress


Back to Top / Wed, June 3, 2026, 1:22 am / permalink 24704 / 5 stories in 2 months /




Related Stories


Apitegromab preserves muscle while patients lose weight on GLP‑1s / 2 months

Merck and Moderna report positive phase‑3 melanoma vaccine results / 12 days

Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 14 days

First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 24 days

Perioperative advances reshape muscle‑invasive bladder cancer care / 5 wks

Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 5 wks

EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 1 month

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Olfaction, Reproductive Health, Neuroscience and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.